Primary-source record
The FDA accepted uniQure's BLA for ifezuntirgene inilparvovec (AMT-130) for Huntington’s disease under the Accelerated Approval pathway and granted Priority Review, setting a PDUFA target action date of May 1, 2027. The FDA also tentatively plans an advisory committee meeting. The BLA is supported by Phase 1/2 data versus external controls; a confirmatory Phase 3 trial is planned to start screening by end of 2026.
EX-99.1 2 tm2628699d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease ~ FDA sets PDUFA target action date of May 1, 2027 ~ ~ If approved, ifezuntirgene inilparvovec will be the world’s first disease-modifying treatment for Huntington’s disease ~ Lexington, MA and Amsterdam, the Netherlands, November 2, 2026 — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for ifezuntirgene inilparvovec, an investigational gene therapy for the treatment of Huntington’s disease submitted under the Accelerated Approval pathway. The application has been granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027. In its acceptance letter, the FDA stated that they are tentatively planning to discuss this application at an Advisory Committee meeting. The Company will be notified once the date and timelines have been finalized. “The FDA’s acceptance of our BLA for review marks an important milestone for the Huntington’s disease community, which has waited generations for a treatment that changes the course of this devastating disease," stated Matt Kapusta, chief executive officer of uniQure